A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Knee Pain Chronic
- Osteoarthritis (Knee)
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Masking Description: The treatment assigned to each subject is blinded to the subject, investigators, and sponsor study team.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 35 years and 85 years
- Gender
- Both males and females
Description
This study is to evaluate the analgesic efficacy and safety of resiniferatoxin administered intra-articularly to subjects with moderate to severe knee pain due to osteoarthritis (OA).
This study is to evaluate the analgesic efficacy and safety of resiniferatoxin administered intra-articularly to subjects with moderate to severe knee pain due to osteoarthritis (OA).
Tracking Information
- NCT #
- NCT04044742
- Collaborators
- Not Provided
- Investigators
- Study Director: Monica Luchi, MD Sorrento Therapeutics, Inc.
Get Well Soon